Sunshine Biopharma Profit Margin

The latest profit margin for SBFM is -17.01% as of March 2026. That compares with -13.88% in the prior-year period — down 22.6% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Sunshine Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, SBFM's profit margin moved from -13.88% to -17.01% — a 22.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sunshine Biopharma's valuation or profitability profile.

Against Healthcare companies, SBFM currently prints -17.01% for profit margin, while the sector average sits near 15.58%. That is roughly 209.2% below the sector mean. Large gaps often invite a closer look at Sunshine Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Sunshine Biopharma converts resources into returns. At -17.01%, SBFM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13.88% in the prior-year period — down 22.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SBFM's profit margin (-17.01%), review year-over-year change from -13.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.